A Randomized, Double-Blind, Placebo-Controlled Phase ??? Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
Latest Information Update: 05 Feb 2026
At a glance
- Drugs CM 326 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Most Recent Events
- 05 Feb 2026 New trial record